Smart Immune
Created in 2017
Up & running (A)
Existing signals show a regular activitySocial networks
6,568Activities
Technologies
Entity types
Location
Faculté de Médecine - Site Cochin, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 32
Engaged catalyst
25
0 0Added in Motherbase
2 years, 1 month ago
Value proposition
Pioneering thymus-empowered T-cell platform to fight cancer and infection
Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.
Biotechnology, Cell therapy, CAR T, Immuno-oncology, NK cells, T cells, Immune reconstitution, T cell progenitors, Lymphoid progenitors, Naive cells, HSC differentiation, and Thymic selectionOriginal language
Pioneering thymus-empowered T-cell platform to fight cancer and infection
Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France, at Paris Biotech Santé.
Unlocking the power of allogeneic T-cell therapies to fight cancer and infection
Smart Immune is a clinical-stage biotechnology company developing ProTcell a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system against cancers and infections.
https://www.smart-immune.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Gouvernement | Other | ||
 European Innovation Council and SMEs Executive Agency (EISMEA) Startup accelerator & VC | European Innovation Council and SMEs Executive Agency (EISMEA) Startup accelerator & VC | Other 20 Dec 2023 | | |
 OECD - OCDE International development, International Affairs | OECD - OCDE International development, International Affairs | Other 23 Sep 2024 | | |
 | Biotechnology Innovation Organization | Other 8 Jun 2023 | | |
 Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Other 14 May 2024 | | |
 Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Other 22 Mar 2024 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 11 Feb 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 13 Oct 2024 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 2 Dec 2024 | | |
 L'Express Media, Newspaper Publishing | L'Express Media, Newspaper Publishing | Other 22 Mar 2024 | | |